MEDICINA
Fachbereich
Hospital de Sant Pau i Santa Tecla
Tarragona, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital de Sant Pau i Santa Tecla (7)
2017
-
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250
2013
-
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome
Leukemia Research, Vol. 37, Núm. 7, pp. 769-776
2012
-
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease
Haematologica, Vol. 97, Núm. 4, pp. 616-621
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2010
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Haematologica, Vol. 95, Núm. 3, pp. 424-431
2009
-
Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study
Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 4, pp. 512-516